Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zoetis ( (ZTS) ) has issued an update.
On December 15, 2025, Zoetis announced a proposed private offering of $1.75 billion in convertible senior notes due 2029, with an option for initial purchasers to buy an additional $250 million, targeted exclusively at qualified institutional buyers under Rule 144A. The company plans to use substantially all of the net proceeds to fund capped call transactions and to repurchase its common stock under its existing $6 billion share repurchase program, with buybacks expected to continue through no later than the first quarter of 2026. The capped call structure is designed to mitigate dilution from potential note conversions and manage any excess cash payments, while related hedging and concurrent share repurchases may affect the trading price of Zoetis’ common stock and the notes, underscoring the transaction’s role as both a financing and capital-return mechanism for shareholders.
The most recent analyst rating on (ZTS) stock is a Buy with a $160.00 price target. To see the full list of analyst forecasts on Zoetis stock, see the ZTS Stock Forecast page.
Spark’s Take on ZTS Stock
According to Spark, TipRanks’ AI Analyst, ZTS is a Outperform.
Zoetis’ overall stock score reflects its strong financial performance and strategic initiatives, which are slightly offset by bearish technical indicators and market challenges. The company’s commitment to innovation and shareholder value, as evidenced by recent corporate events, supports a positive long-term outlook despite near-term technical pressures.
To see Spark’s full report on ZTS stock, click here.
More about Zoetis
Zoetis Inc., listed on the NYSE under the ticker ZTS, is the world’s leading animal health company, focused on advancing care for animals through a portfolio and pipeline of medicines, vaccines, diagnostics and technologies. With more than 70 years of innovation, it serves veterinarians, pet owners and livestock producers in over 100 countries, targeting both companion animal and livestock health markets.
Average Trading Volume: 4,497,600
Technical Sentiment Signal: Sell
Current Market Cap: $54.31B
Find detailed analytics on ZTS stock on TipRanks’ Stock Analysis page.